Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges
By Paul Ziobro
Gilead Sciences posted higher first-quarter sales, but swung to a steep loss due to charges related to recent acquisitions, prompting the company to cut its per-share profit outlook.
The Foster City, Calif.-based biopharmaceutical company reported a loss of $4.17 billion, or $3.34 a share, compared with a profit of $1.01 billion, or 81 cents a share, in the same quarter a year ago.
The latest quarter's results were impacted by a $3.9 billion in-process research and development charge related to its recent $4.3 billion acquisition of CymaBay Therapeutics, as well as a pretax impairment of $2.4 billion related to assets acquired from Immunomedics in 2020.
Adjusted for certain items, Gilead said its per-share loss came to $1.32 a share. Analysts were looking a loss of $1.49 a share, according to FactSet.
Total revenue rose about 5% to $6.67 billion, ahead of analyst expectations for $6.36 billion, primarily due to higher sales of HIV, oncology and liver disease products.
For the full-year, Gilead now expects per-share earnings of between 10 cents and 50 cents, down from its prior view of $5.15 to $5.55. On an adjusted basis, the company expects per-share earnings of $3.45 to $3.85, down from a prior range of $6.85 to $7.25.
It backed its top-line outlook.
Write to Paul Ziobro at paul.ziobro@wsj.com
-0-
Gileadisprovidingfull-year2024guidancebelow:
• Totalproductsalesbetween$27.1billionand$27.5billion.
• Totalproductsales,excludingVeklury,between$25.8billionand$26.2billion.
• TotalVeklurysalesofapproximately$1.3billion.
• DilutedEPSbetween$5.15and$5.55.
• Non-GAAPdilutedEPSbetween$6.85and$7.25.
(END) Dow Jones Newswires
April 25, 2024 16:39 ET (20:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks